Physician profile
Leesha M Ellis Cox
NPI 1598764698
$653,194.72
in general payments reported to CMS, 2019-2025
23 companies · $138K in 2025
The $138K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $18K · 2021: $25K · 2022: $126K · 2023: $153K · 2024: $170K · 2025: $138K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $374K · Travel and Lodging: $42K · Consulting Fee: $24K · Food and Beverage: $21K · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $374,286.00 |
| Travel and Lodging | $42,496.07 |
| Consulting Fee | $23,670.00 |
| Food and Beverage | $20,855.49 |
| Education | $210.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $378,951.56 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $219,004.93 | 2020-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $38,656.44 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $4,808.56 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $2,414.60 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $1,688.02 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $1,446.19 | 2020-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $1,216.94 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $1,117.18 | 2019-2025 | Abilify Maintena, Rexulti |
| Ironshore Pharmaceuticals INC. | $971.04 | 2019-2024 | Jornay Pm |
| Abbvie INC. | $837.87 | 2021-2025 | |
| Indivior INC. | $650.88 | 2019-2024 | Perseris |
| Axsome Therapeutics, INC. | $386.18 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $367.51 | 2020-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $209.14 | 2021-2025 | Qelbree |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $208.60 | 2019 | |
| Tris Pharma INC | $90.82 | 2024-2025 | Dyanavel Xr |
| Biogen, INC. | $74.86 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $31.07 | 2025 | Jornay Pm |
| Luye Pharma (USA) Ltd. | $19.57 | 2025 | Erzofri Extended-Release |
| Shire North American Group INC | $17.01 | 2019 | |
| Noven Therapeutics, LLC | $13.22 | 2024 | Secuado, Xelstrym |
| Adlon Therapeutics L.P. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leesha Ellis Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.